Statistiche di base
| LEI | 549300H68IVCRKSGSL94 |
| CIK | 1740279 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IN8bio, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 7, 2025 |
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights • Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years. • Received the Host Region USA East Abstract Award at ISCT 20 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, IN |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 4, 2025 |
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of IN8bio, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IN8BIO, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) IN8bio, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CE |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 2, 2025 |
Exhibit 99.1 IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival • Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol • INB-200 is well-tolerated, showing no serious toxic |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, I |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2025 |
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Exhibit 99.1 IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights • Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meeti |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 28, 2025 |
EX-4.3 Exhibit 4.3 IN8BIO, INC. AMENDMENT NO. 1 TO SERIES B COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO SERIES B COMMON STOCK PURCHASE WARRANT, dated as of April [•], 2025 (this “Amendment”), amends that certain SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of December 13, 2023, by IN8bio, Inc. (the “Company”) for the benefit of the holder thereof or its permitted assi |
|
| April 28, 2025 |
Form of Amendment to Series B Warrant EX-4.4 Exhibit 4.4 IN8BIO, INC. AMENDMENT NO. 1 TO SERIES B COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO SERIES B COMMON STOCK PURCHASE WARRANT, dated as of April [•], 2025 (this “Amendment”), amends that certain SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of December 13, 2023, by IN8bio, Inc. (the “Company”) for the benefit of the holder thereof or its permitted assi |
|
| April 28, 2025 |
EX-99.1 Exhibit 99.1 IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 • First gamma-delta (gd) TCE to demonstrate significant gd T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS) • INB-600 TCE platform signif |
|
| April 28, 2025 |
EX-10.1 Exhibit 10.1 IN8BIO, INC. AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of April 27, 2025 (the “Effective Date”), amends that certain Securities Purchase Agreement (the “Agreement”), dated as of September 30, 2024, between IN8bio, Inc. (the “Company”) and each of the Investors party thereto. Capitalized t |
|
| April 28, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 28, 2025 |
Exhibit 10.2 IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 April , 2025 Re: Inducement Offer to Exercise Series A Warrant and Series B Warrant Dear Holder: IN8BIO, INC. (the “Company”), a Delaware corporation, is pleased to offer to you the opportunity to exercise for cash all or a portion of your Series A warrant and/or Series B warrant to purchase shares of the Company’s com |
|
| April 28, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 28, 2025 |
EX-10.3 Exhibit 10.3 IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 April , 2025 To the Holder of Series A and Series B Warrants to Purchase Common Stock Re: Inducement Offer to Exchange Series A and Series B Warrants to Purchase Common Stock Dear Holder: IN8BIO, INC. (the “Company”) is pleased to offer to you the opportunity to receive pre-funded warrants to purchase sh |
|
| April 28, 2025 |
Form of Amendment to Series A Warrant issued to Participating Holders EX-4.2 Exhibit 4.2 IN8BIO, INC. AMENDMENT NO. 2 TO SERIES A COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 2 TO SERIES A COMMON STOCK PURCHASE WARRANT, dated as of April [•], 2025 (this “Amendment”), amends that certain SERIES A COMMON STOCK PURCHASE WARRANT ([as previously amended,] the “Warrant”), dated as of December 13, 2023, by IN8bio, Inc. (the “Company”) for the benefit of the holder ther |
|
| March 17, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 17, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 13, 2025 |
EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of March 14, 2024 (the “Effective Date”), by and between Kate M. |
|
| March 13, 2025 |
Description of the Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF THE REGISTRANTS’ SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes selected information regarding our capital stock, as well as provisions of; (i) our amended and restated certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the general Corporation Law of the State of Delaware |
|
| March 13, 2025 |
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights Exhibit 99.1 IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights • Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free • Expanded pipeline with INB-600 platform, featuring nov |
|
| March 13, 2025 |
IN8BIO, Inc. Non-Employee Director Compensation Policy Exhibit 10.9 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No. |
|
| March 13, 2025 |
IN8BIO, Inc. Insider Trading Policy Policy Principles • Employees, directors, other applicable members of management and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of IN8bio, Inc. and its subsidiaries (together, the “Company”) are responsible for understanding the obligations that come with having access to material nonpublic information and wanting to tr |
|
| March 13, 2025 |
IN8BIO, Inc. Non-Employee Director Compensation Policy Exhibit 10.10 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy” |
|
| March 13, 2025 |
tm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K tm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39692 IN8BIO, INC. |
|
| March 13, 2025 |
EXHIBIT 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of January 20, 2021 (the “Effective Date”), by and between Patrick McCall (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wishes |
|
| March 13, 2025 |
EXHIBIT 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of October 7, 2021 (the “Effective Date”), by and between Trishna Goswami, MD (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wis |
|
| March 13, 2025 |
EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT EXHIBIT 10.21 EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT In consideration of my employment or continued employment by IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”), the compensation paid to me now and during my employment with the Company, and the Company’s agreement to provide me with access to its Con |
|
| March 13, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) IN8bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value pe |
|
| March 13, 2025 |
IN8bio, Inc. Incentive Compensation Recoupment Policy Approved: October 23, 2023 Exhibit 97 IN8bio, Inc. Incentive Compensation Recoupment Policy Approved: October 23, 2023 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of IN8bio, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Polic |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 3, 2025 |
Exhibit 99.1 IN8bio Announces Advanced Gamma-Delta (gd) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases • Proprietary platform represents the first known approach capable of sustained gd T cell expansion, eliminating target cells with robust potency • INB-619, a next generation gd TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as gd |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 11, 2025 |
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients EX-99.1 Exhibit 99.1 IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients • 100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months • AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-worl |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 10, 2024 |
Exhibit 99.1 IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting • INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease afte |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 25, 2024 |
Exhibit 99.1 IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting • 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) a |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 12, 2024 |
IN8BIO, Inc. Non-Employee Director Compensation Policy 294993051 v2 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| November 12, 2024 |
Separation Agreement, by and between the Company and Trishna Goswami, dated as of September 6, 2024 September 6, 2024 Via Email Dr. Trishna Goswami Dear Trishna: This letter sets forth the substance of the separation agreement (the “Agreement”) that IN8bio, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be September 6, 2024 (the “Separation Date”). 2. Accrued Compensatio |
|
| November 12, 2024 |
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial - INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control - Closed private placement for net proceeds of $11. |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 12, 2024 |
IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or h |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BI |
|
| November 12, 2024 |
L E A S E A G R E E M E N T By and between SLOSS MARTIN BISCUIT, LTD., by and through its Agent, SLOSS REAL ESTATE COMPANY, INC. (together “Landlord”) And IN8BIO, INC. (“Tenant”) dated March 16, 2024 for Martin Biscuit Building 2901 2nd Avenue South Birmingham, AL 35233 Suite Number 210 containing approximately 8,116 square feet of Rentable Floor Area Term: 60-1/2 months 23134410.6 TABLE OF CONTEN |
|
| November 12, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 270) SECOND AMENDMENT TO LEASE AGREEMENT (Suite 270) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| November 12, 2024 |
55,494,910 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282984 PROSPECTUS 55,494,910 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus or their donees, pledgees, assignees, transferees, distributees or other successors-in-interest (the “selling stockholders”) of up to an aggregate of 55,494,910 shares of our |
|
| November 12, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 230) SECOND AMENDMENT TO LEASE AGREEMENT (Suite 230) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| November 8, 2024 |
IN8BIO, Inc. 350 5th Avenue, Suite 5330 New York, New York 10118 CORRESP IN8BIO, Inc. 350 5th Avenue, Suite 5330 New York, New York 10118 November 8, 2024 VIA EDGAR Securities and Exchange Commission Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: IN8bio, Inc. (CIK No. 0001740279) Registration Statement on Form S-3 File No. 333-282984 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to R |
|
| November 4, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IN8bio, Inc. |
|
| November 4, 2024 |
As filed with the Securities and Exchange Commission on November 4, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 4, 2024 Registration No. |
|
| October 11, 2024 |
INAB / IN8bio, Inc. / BIOS Fund II, LP - SC 13D/A Activist Investment SC 13D/A 1 tm2425783d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) IN8bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45674E 109 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas 76107 Tel: (8 |
|
| October 9, 2024 |
INAB / IN8bio, Inc. / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E109 (CUSIP Number) October 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| October 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2024, between IN8bio, Inc., a Delaware corporation (the “Company”), and each of the investors identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively the “Investors”). RECITALS A. The Company and each Investor is |
|
| October 1, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2024 by and among IN8bio, Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of September 30, 2024, between the Company and each of the Investors identified on the signature pages thereto (t |
|
| October 1, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 1, 2024 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 1, 2024 |
Exhibit 4.3 IN8BIO, INC. AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT, dated as of [•], 2024 (this “Amendment”), amends that certain COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of December 13, 2023, by IN8bio, Inc. (the “Company”) for the benefit of the holder thereof or its permitted assigns (“Holder”). The Company and Holder a |
|
| October 1, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 17, 2024 |
INAB / IN8bio, Inc. / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E109 (CUSIP Number) June 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 6, 2024 |
Exhibit 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) to that certain Employment Agreement, effective January 20, 2021 (the “Agreement”), by and between you and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company,” and collectively with you, the “Parties”) is entered into as of this 30th day of August, 2024. W |
|
| September 6, 2024 |
Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) to that certain Employment Agreement, effective December 30, 2020 (the “Agreement”), by and between you and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company,” and collectively with you, the “Parties”) is entered into as of this 30th day of August, 2024. |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| September 6, 2024 |
Exhibit 10.5 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) to that certain Employment Agreement, effective March 14, 2024 (the “Agreement”), by and between you and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company,” and collectively with you, the “Parties”) is entered into as of this 30th day of August, 2024. WHE |
|
| September 6, 2024 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This amendment (this “Amendment”) to that certain Employment Agreement, effective October 7, 2021 (the “Agreement”), by and between you and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company,” and collectively with you, the “Parties”) is entered into as of this 30th day of August, 2024. WH |
|
| September 6, 2024 |
Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This amendment (this “Amendment”) to that certain Employment Agreement, effective December 1, 2020 (the “Agreement”), by and between you and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company,” and collectively with you, the “Parties”) is entered into as of this 30th d |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| September 4, 2024 |
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia Exhibit 99.1 IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia - Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. - Suspe |
|
| August 12, 2024 |
Exhibit 99.1 IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 • Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission antic |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 12, 2024 |
Up to $14,700,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $14,700,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2024 |
L E A S E A G R E E M E N T By and between SLOSS MARTIN BISCUIT, LTD., by and through its Agent, SLOSS REAL ESTATE COMPANY, INC. (together “Landlord”) And IN8BIO, INC. (“Tenant”) dated March 16, 2024 for Martin Biscuit Building 2901 2nd Avenue South Birmingham, AL 35233 Suite Number 210 containing approximately 8,116 square feet of Rentable Floor Area Term: 60-1/2 months 23134410.6 TABLE OF CONTEN |
|
| August 8, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 270) SECOND AMENDMENT TO LEASE AGREEMENT (Suite 270) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| August 8, 2024 |
IN8BIO, Inc. Non-Employee Director Compensation Policy 294993051 v2 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| August 8, 2024 |
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights 302406282 v3 IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress - Continues to be an industry leader in the manufacturing |
|
| August 8, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 230) SECOND AMENDMENT TO LEASE AGREEMENT (Suite 230) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, IN |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 13, 2024 |
EX-99.1 Exhibit 99.1 IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 • 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. • Da |
|
| June 3, 2024 |
EX-99.1 Exhibit 99.1 IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting 92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expe |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights 302406282 v3 IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient in autologous arm of INB-400 Phase 2 clinical trial for patients with newly diagnosed GBM NEW YORK, May 9, 2024 - IN8bio, Inc. |
|
| May 9, 2024 |
294993051 v2 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, I |
|
| May 9, 2024 |
Lease Agreement (Suite 210) between the Company and Sloss Martin Biscuit, Ltd., dated March 16, 2024 L E A S E A G R E E M E N T By and between SLOSS MARTIN BISCUIT, LTD., by and through its Agent, SLOSS REAL ESTATE COMPANY, INC. (together “Landlord”) And IN8BIO, INC. (“Tenant”) dated March 16, 2024 for Martin Biscuit Building 2901 2nd Avenue South Birmingham, AL 35233 Suite Number 210 containing approximately 8,116 square feet of Rentable Floor Area Term: 60-1/2 months 23134410.6 TABLE OF CONTEN |
|
| May 9, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 270) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| May 9, 2024 |
SECOND AMENDMENT TO LEASE AGREEMENT (Suite 230) This Second Amendment to Lease Agreement (this “Amendment”) is made and entered into as of March 16, 2024, by and between SLOSS MARTIN BISCUIT, LTD. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $8,900,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File N |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 14, 2024 |
EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT EXHIBIT 10.21 EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT In consideration of my employment or continued employment by IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”), the compensation paid to me now and during my employment with the Company, and the Company’s agreement to provide me with access to its Con |
|
| March 14, 2024 |
Non-Employee Director Compensation Policy (as amended December 5, 2023). Exhibit 10.10 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy” |
|
| March 14, 2024 |
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights • Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients Alive and Progression Free Past 12 Months • Presented Positive Results from a Phase 1 Study in Newly Diagnosed Glioblastoma (GBM) Demonstrating All Patients Treated with INB-200 Exceeded Progression-Free Survival (PFS) of Seven Months at the Society for Neuro-Oncology (SNO) 28th Annual Meeting • Appointed Dr. |
|
| March 14, 2024 |
EXHIBIT 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of January 20, 2021 (the “Effective Date”), by and between Patrick McCall (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wishes |
|
| March 14, 2024 |
Non-Employee Director Compensation Policy (as amended November 30, 2021). Exhibit 10.9 IN8BIO, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| March 14, 2024 |
EXHIBIT 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of October 7, 2021 (the “Effective Date”), by and between Trishna Goswami, MD (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wis |
|
| March 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2024 |
IN8bio, Inc. Incentive Compensation Recoupment Policy, dated October 23, 2023. Exhibit 97 IN8bio, Inc. Incentive Compensation Recoupment Policy Approved: October 23, 2023 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of IN8bio, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Polic |
|
| March 14, 2024 |
Description of the Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF THE REGISTRANTS’ SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes selected information regarding our capital stock, as well as provisions of; (i) our amended and restated certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the general Corporation Law of the State of Delaware |
|
| March 14, 2024 |
EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of March 14, 2024 (the “Effective Date”), by and between Kate M. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39692 IN8BIO, INC. (E |
|
| February 13, 2024 |
US45674E1091 / IN8BIO INC / Ho William Tai-Wei - SC 13G/A Passive Investment SC 13G/A 1 tm246100d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E 109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the |
|
| January 19, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) IN8bio, Inc. |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 S-8 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 18, 2024 |
42,703,475 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276504 PROSPECTUS 42,703,475 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus or their donees, pledgees, assignees, transferees, distributees or other successors-in-interest (the “selling stockholders”) of up to an aggregate of 42,703,475 shares of our |
|
| January 16, 2024 |
IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 January 16, 2024 VIA EDGAR Securities and Exchange Commission Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: IN8bio, Inc. (CIK No. 0001740279) Registration Statement on Form S-3 File No. 333-276504 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| January 12, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IN8bio, Inc. |
|
| January 12, 2024 |
As filed with the Securities and Exchange Commission on January 12, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. |
|
| December 15, 2023 |
Exhibit 99.1: Joint Filing Agreement Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of |
|
| December 15, 2023 |
INAB / IN8bio Inc / BIOS Fund II, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) IN8bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45674E 109 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas 76107 Tel: (817) 984-9197 With a Copy to: Rick Jordan P |
|
| December 15, 2023 |
Exhibit 99.2: Power of Attorney EX-99.2 3 tm2332973d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 POWER OF ATTORNEY The undersigned hereby constitute and appoint Daniel Schwarz, the lawful attorney-in-fact and agent with full power and authority to execute and file on the undersigned’s behalf, any and all instruments including Forms 3, 4 and 5, and Schedules 13D and 13G (collectively, the “Filings”), and any amendments, supplements or s |
|
| December 15, 2023 |
US45674E1091 / IN8BIO INC / Transcend Partners Opportunity Fund I LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E 109 (CUSIP Number) December 13, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| December 15, 2023 |
US45674E1091 / IN8BIO INC / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E109 (CUSIP Number) December 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 11, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 11, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 11, 2023, between IN8bio, Inc., a Delaware corporation (the “Company”), and each of the investors identified on Schedule I attached hereto (each, including its successors and assigns, an “Investor” and collectively the “Investors”). RECITALS A. The Company and each Investor is e |
|
| December 11, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2023 by and among IN8bio, Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of December 11, 2023, between the Company and each of the Investors identified on Schedule I attached thereto (the |
|
| December 11, 2023 |
EX-99.1 Exhibit 99.1 IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to help accelerate advancement of the Company’s gamma-delta T cell therapies NEW YORK, Dec. 11, 2 |
|
| December 11, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 11, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 7, 2023 |
Exhibit 10.1 IN8BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) |
|
| December 7, 2023 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF IN8BIO, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of IN8bio, Inc. (the “corporation”) in the State of Delaware shall be as set forth in the Amended and Restated Certificate of Incorporation of the corporation, as the same may be amended or restated from time to time (the “Certificate of Inco |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 20, 2023 |
Exhibit 99.1 IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort 2 remain alive beyond two years Additi |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BI |
|
| November 9, 2023 |
IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update • Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number: 4853) • Held Research & Development Day, featuring Leo Luznik, M.D. from Johns Hopkins University and Michae |
|
| October 12, 2023 |
Exhibit 99.1 IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma • Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). • |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 18, 2023 |
As filed with the Securities and Exchange Commission on August 18, 2023 As filed with the Securities and Exchange Commission on August 18, 2023 Registration No. |
|
| August 18, 2023 |
As filed with the Securities and Exchange Commission on August 18, 2023 As filed with the Securities and Exchange Commission on August 18, 2023 Registration No. |
|
| August 18, 2023 |
As filed with the Securities and Exchange Commission on August 18, 2023 As filed with the Securities and Exchange Commission on August 18, 2023 Registration No. |
|
| August 18, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) IN8bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Equity Incentive Plan (options) |
|
| August 11, 2023 |
EX-99.1 2 d514664dex991.htm EX-99.1 CUSIP No. 45674E 109 Page 8 of 8 Pages EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of August 11, 2023, is by and among Transcend Partners Opportunity Fund I LLC and Emily Fairbairn (collectively, the “Reporting Persons”). Each of the Reporting Persons may be required to file with the U.S. Securities and Exchange Commission a statement |
|
| August 11, 2023 |
US45674E1091 / IN8BIO INC / Transcend Partners Opportunity Fund I LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E 109 (CUSIP Number) August 3, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| August 11, 2023 |
US45674E1091 / IN8BIO INC / Ho William Tai-Wei - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IN8bio, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 45674E 109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 10, 2023 |
Exhibit 10.1 IN8BIO, Inc. Amended and Restated 2023 Equity Incentive Plan Adopted by the Board of Directors: April 29, 2023 Approved by the Stockholders: June 15, 2023 1. General. (a) Successor to and Continuation of Prior Plans. The Plan is the successor to and continuation of the Prior Plans. As of the Effective Date, (i) no additional awards may be granted under the Prior Plans; (ii) the Prior |
|
| August 10, 2023 |
Exhibit 10.2 IN8BIO, Inc. Stock Option Grant Notice (Amended and Restated 2023 Equity Incentive Plan) IN8bio, Inc. (the “Company”), pursuant to its Amended and Restated 2023 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions a |
|
| August 10, 2023 |
IN8BIO, INC. BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical median progression-free survival • INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, IN |
|
| July 31, 2023 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $6,433,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 ( |
|
| July 14, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $2,831,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File N |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
EX-99.1 Exhibit 99.1 IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting • 100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months, respectively. • INB-200 continues to exhibit a manageable safety profile with min |
|
| May 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 17, 2023 |
IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer EX-99.1 Exhibit 99.1 IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer • Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain • The DeltEx platform is the basis for IN8bio’s clinical stage gamma-delta T cell therapeutic candidates and demonstrated the abili |
|
| May 12, 2023 |
IN8BIO, INC. BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update • Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose (RP2D) for the ongoing expansion with clinical updates expected in late 2023. • Progres |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, I |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 1, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 27, 2023 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $2,949,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 ( |
|
| April 26, 2023 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-268288 PROSPECTUS SUPPLEMENT (To prospectus dated on November 21, 2022) Up to $5,949,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 21, 2022 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 ( |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 24, 2023 |
EX-99.1 Exhibit 99.1 IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 • INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL) wh |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 17, 2023 |
EX-99.1 Exhibit 99.1 IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 • INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. • CAR platform leverages the ability of gamma-delta T |
|
| March 30, 2023 |
Employment Agreement between Registrant and Kate Rochlin, dated December 21, 2020. EXHIBIT 10.21 EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT In consideration of my employment or continued employment by IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”), the compensation paid to me now and during my employment with the Company, and the Company’s agreement to provide me with access to its Con |
|
| March 30, 2023 |
Description of the Registrant’s Securities Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANTS’ SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes selected information regarding our capital stock, as well as provisions of; (i) our amended and restated certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the general Corporation Law of the State |
|
| March 30, 2023 |
Employment Agreement between Registrant and Trishna Goswami, dated October 7, 2021 EXHIBIT 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of October 7, 2021 (the “Effective Date”), by and between Trishna Goswami, MD (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wis |
|
| March 30, 2023 |
Employment Agreement between Registrant and Patrick McCall, dated January 20, 2021 EXHIBIT 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of January 20, 2021 (the “Effective Date”), by and between Patrick McCall (the “Executive”) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the “Company”) (Executive and the Company together, the “Parties”). Recitals WHEREAS, the Company wishes |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39692 IN8BIO, INC. (E |
|
| March 30, 2023 |
IN8BIO, INC. BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update • All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated clinical data to be reported at the EBMT Annual Meeting in April 2023. • INB-200 contin |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 23, 2023 |
EX-99.1 Exhibit 99.1 IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue • Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. • Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validate |
|
| January 5, 2023 |
EX-99.1 2 d435564dex991.htm EX-99.1 Exhibit 99.1 IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals • All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastom |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 12, 2022 |
Exhibit 99.1 IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 ? Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months) ? INB-100 continues to demonstrate a manageable safety |
|
| December 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 8, 2022 |
Exhibit 99.1 IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma ? Phase 2 clinical trial initiation expected in 2023 ? Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being presented at the American Society of Hematology (ASH) on Monday, December 12 |
|
| December 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) |
|
| December 6, 2022 |
Exhibit 99.1 IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress ? INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ? Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the GMP manufa |
|
| November 17, 2022 |
IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 CORRESP 1 filename1.htm IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 November 17, 2022 VIA EDGAR Securities and Exchange Commission Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: IN8bio, Inc. Registration Statement on Form S-3 (CIK No. 0001740279) File No. 333-268288 Request for Acceleration of Effective Date Ladies and Gentlemen: Purs |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2022 |
IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ? Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the GMP manufacturing |
|
| November 10, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.6 EXHIBIT 4.6 IN8bio, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated as of IN8BIO, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IN8BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and ha |
|
| November 10, 2022 |
EX-1.2 Exhibit 1.2 IN8BIO, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement November 10, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Truist Securities, Inc. 3333 Peachtree Road NE, 11th Floor Atlanta, Georgia 30326 Ladies and Gentlemen: IN8bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agree |
|
| November 10, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) IN8Bio, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BI |
|
| November 10, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.7 EXHIBIT 4.7 IN8bio, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of IN8BIO, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IN8BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| November 10, 2022 |
Power of Attorney (included on the signature page to this registration statement). S-3 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.8 EXHIBIT 4.8 IN8bio, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of IN8BIO, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between IN8BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| November 10, 2022 |
EX-4.4 Exhibit 4.4 IN8BIO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE Article 1 DEFINITIONS 1 1.1 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 2.1 Designation and Terms of Securities 4 2.2 Form of Securities and Trustee’s Certificate 7 2.3 Denominations: Provisions for P |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 19, 2022 |
Exhibit 99.1 IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering NEW YORK, Aug. 19, 2022 ? IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten pub |
|
| August 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 16, 2022 |
EX-99.2 3 d284938dex992.htm EX-99.2 Exhibit 99.2 IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock NEW YORK, Aug. 16, 2022 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the closing of its previously anno |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 16, 2022 |
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock Exhibit 99.1 IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock NEW YORK, August 11, 2022 ? IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the pricing of an underwritten public offering of 5,394,737 shares o |
|
| August 15, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-266620 PROSPECTUS 5,394,737 Shares We are offering 5,394,737 shares of our common stock at a public offering price of $1.90 per share. Our common stock is listed on the Nasdaq Global Market under the symbol ?INAB.? On August 11, 2022, the last reported sales price of our common stock on the Nasdaq Global Market was $1.98 per s |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, |
|
| August 12, 2022 |
As filed with the Securities and Exchange Commission on August 12, 2022 POS EX 1 d556716dposex.htm POS EX As filed with the Securities and Exchange Commission on August 12, 2022 Registration No. 333-266620 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IN8BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2836 82-5462585 (State or other jurisdiction of inco |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 12, 2022 |
IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting. ? Presented data from Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM showing five of six fully dosed patients exceeded both median |
|
| August 9, 2022 |
Form of Underwriting Agreement. EX-1.1 2 d251917dex11.htm EX-1.1 Exhibit 1.1 shares of Common Stock and Prefunded Warrants IN8BIO, INC. UNDERWRITING AGREEMENT August , 2022 H.C. Wainwright & Co., LLC as the Representative of the several underwriters, if any, named in Schedule I hereto 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: IN8bio, Inc., a Delaware corporation (the “Company”), proposes to sell s |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 9, 2022. Table of Contents As filed with the Securities and Exchange Commission on August 9, 2022. |
|
| August 9, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.8 IN8BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of IN8bio, Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an ?Non-Employee Director?) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this ?Policy?) |
|
| August 9, 2022 |
Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT IN8BIO, INC. Warrant Shares: Initial Exercise Date: August , 2022 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (t |
|
| August 8, 2022 |
CORRESP 1 filename1.htm August 8, 2022 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: IN8bio, Inc. Registration Statement on Form S-1 (Registration No. 333-266620) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), as managing underwriter for the above-referenced offering, he |
|
| August 8, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| August 8, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on August 8, 2022. |
|
| August 8, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2022 |
IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 August 8, 2022 VIA EDGAR Securities and Exchange Commission Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: IN8bio, Inc. Draft Registration Statement on Form S-1 (CIK No. 0001740279) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Re |
|
| July 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 27, 2022 |
Exhibit 99.1 IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients ? All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year. ? Patients remain in morp |
|
| July 20, 2022 |
Table of Contents Confidential Treatment Requested by IN8bio, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on July 20, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITI |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2022 |
IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update ? Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data. ? INB-100 patient update at European Group for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting demonstrated that all three trea |
|
| May 12, 2022 |
EX-FILING FEES 4 d313321dexfilingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Equity Incentive Plan (Common stock, $0.0001 par value per share) Other 939,062(2) $2.69(4) $2,521, |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39692 IN8BIO, |
|
| May 12, 2022 |
As filed with the Securities and Exchange Commission on May 12, 2022 As filed with the Securities and Exchange Commission on May 12, 2022 Registration No. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 28, 2022 |
Exhibit 99.1 IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant ? All three patients with high-risk or relapsed acute-myeloid leukemia (AML) dosed to-date with INB-100 demonstrated durable remissions at 23.3, 21.0, and 9.3 months post-BMT, respectively. ? Immune syste |
|
| March 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 17, 2022 |
IN8BIO, INC. CONDENSED BALANCE SHEETS (In thousands, except share and per share data) Exhibit 99.1 IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update ? All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated progression free survival (PFS) to date. ? All patients treated with INB-100, in clinical development for |
|
| March 17, 2022 |
EXHIBIT 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of October 7, 2021 (the ?Effective Date?), by and between Trishna Goswami, MD (the ?Executive?) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the ?Company?) (Executive and the Company together, the ?Parties?). Recitals WHEREAS, the Company wis |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39692 IN8BIO, INC. (E |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 17, 2022 |
EX-4.3 2 inab-ex43.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANTS’ SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes selected information regarding our capital stock, as well as provisions of; (i) our amended and restated certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the general Corporatio |
|
| March 17, 2022 |
EXHIBIT 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of January 20, 2021 (the ?Effective Date?), by and between Patrick McCall (the ?Executive?) and IN8bio, Inc., its subsidiaries, parents, affiliates, predecessors, successors and assigns (together, the ?Company?) (Executive and the Company together, the ?Parties?). Recitals WHEREAS, the Company wishes |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 IN8bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39692 82-5462585 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 16, 2021 |
Exhibit 99.1 IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant ? The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients ? 3 patients have been treated to date, al |
